Valneva Ixiaro travel vaccine: what US travelers should know

Valneva Ixiaro is a Japanese encephalitis travel vaccine used for adults and children visiting Asia and the Western Pacific. Learn how it works, who needs it, and how it fits into US travel health planning.

Valneva Ixiaro is a Japanese encephalitis travel vaccine used to help protect adults and children who visit parts of Asia and the Western Pacific where the virus is found FDA, 02/25/2022. The vaccine is manufactured by Valneva Austria and is available in the United States by prescription through travel clinics and selected healthcare providers CDC, 01/05/2024.

As of: 05/31/2026 | Reading time: approx. 8 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Valneva Ixiaro travel vaccine
• Category: Japanese encephalitis vaccine for travelers
• Brand/Manufacturer: Valneva Austria GmbH
• Primary Use Cases: Travel vaccination before visiting JE risk regions
• Availability: Prescription vaccine through US travel clinics
• Core Markets: United States, Europe, Asia-Pacific travel markets

What Valneva Ixiaro travel vaccine is and how it works

Valneva Ixiaro travel vaccine is an inactivated Japanese encephalitis vaccine indicated for the prevention of disease in adults, adolescents, children, and infants aged 2 months and older who plan travel to endemic areas EMA, 11/16/2023.

The vaccine contains an inactivated strain of Japanese encephalitis virus adsorbed onto aluminum hydroxide, which acts as an adjuvant to enhance the immune response FDA, 03/30/2022. Because the virus is inactivated, it cannot cause the disease itself when administered as recommended.

Ixiaro is given as an intramuscular injection, usually in the upper arm in adults and older children or the thigh in younger children, following a two-dose primary series separated by 28 days for most age groups CDC, 01/05/2024. A booster dose can be considered for travelers with ongoing exposure risk.

Japanese encephalitis is a mosquito-borne viral infection present in rural and peri-urban parts of Asia and the Western Pacific; most infections are asymptomatic, but a small percentage develop severe neurologic disease with high mortality and potential long-term disability CDC, 10/18/2023. Vaccination is one important preventive tool alongside mosquito bite avoidance.

Why Valneva Ixiaro travel vaccine matters for US travelers

For US residents traveling to countries where Japanese encephalitis is endemic, especially for longer stays in rural areas, Ixiaro offers a preventive option recommended in official US travel health guidance CDC Yellow Book, 02/01/2024. Many US primary care practices rely on travel clinics for this specialized vaccine.

US health authorities emphasize that Japanese encephalitis risk is generally low for short urban trips but can be meaningful for travelers spending extended time in rural areas, visiting during transmission season, or engaging in outdoor activities at night CDC, 02/01/2024. In those situations, clinicians may discuss Ixiaro as a preventive option.

Because there is no specific antiviral treatment for Japanese encephalitis, prevention through mosquito control and vaccination is central to management strategies cited by US and international public health agencies. Clinical care focuses on supportive treatment in hospital once severe disease develops, underscoring the value of prevention.

Valneva Ixiaro travel vaccine in the US and global market

Ixiaro is currently the only Japanese encephalitis vaccine licensed for use in the United States, according to US regulatory and public health documents that describe available JE vaccines for travelers CDC, 01/05/2024. It is distributed to US travel clinics and vaccination centers that stock specialized travel immunizations.

Outside the United States, the same vaccine is marketed under the names Ixiaro or Jespect in various regions and is used in Europe, Canada, Australia, and other markets where residents travel to JE-endemic destinations, as described in European regulatory assessment reports EMA, 11/16/2023. These documents highlight its role in travel medicine globally.

In the US travel health ecosystem, Ixiaro is typically offered alongside other travel vaccines such as hepatitis A, typhoid, rabies pre-exposure, and yellow fever (where available through certified centers). This positioning reflects its role as part of a broader pre-travel consultation for itineraries that include rural Asia or the Western Pacific.

• Inactivated Japanese encephalitis vaccine for travelers
• Two-dose primary series plus possible booster for ongoing risk
• Used for trips to parts of Asia and Western Pacific
• Available in the US through prescription travel clinics
• Part of comprehensive pre-travel health planning

Frequently Asked Questions About Valneva Ixiaro travel vaccine

Who should consider Valneva Ixiaro travel vaccine?
US guidance states that JE vaccination should be considered for people spending significant time in rural areas of endemic countries, particularly during transmission season CDC Yellow Book, 02/01/2024.

How far in advance should the vaccine series be completed?
Travel medicine guidance recommends starting the Ixiaro series early enough to complete both doses at least one week before potential exposure in the destination, allowing the immune response to develop adequately.

Is Valneva Ixiaro travel vaccine suitable for children?
Regulatory information indicates that the vaccine is approved for use from 2 months of age in certain markets, including the US, with age-adapted dosing and schedules FDA, 03/30/2022. Parents should consult a pediatric travel clinic.

Valneva Ixiaro travel vaccine is produced by Valneva Austria, a subsidiary of Valneva SE, a specialty vaccine company headquartered in Europe that focuses on vaccines for infectious diseases with unmet medical needs.

Valneva SE is listed on Euronext Paris and Nasdaq, and its issuer identification for capital markets includes the ISIN FR0013280286 as a technical reference for investors following the broader company.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.